{"organizations": [], "uuid": "1e0508bd1bfa981652158fc67cbd16c228670cfe", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180308.html", "section_title": "Archive News &amp; Video for Thursday, 08 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-acelrx-plans-to-resubmit-the-dsuvi/brief-acelrx-plans-to-resubmit-the-dsuvia-new-drug-application-in-q2-idUSASB0C9J8", "country": "US", "domain_rank": 408, "title": "BRIEF-AcelRX Plans To Resubmit The Dsuvia New Drug Application In Q2", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-09T05:22:00.000+02:00", "replies_count": 0, "uuid": "1e0508bd1bfa981652158fc67cbd16c228670cfe"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-acelrx-plans-to-resubmit-the-dsuvi/brief-acelrx-plans-to-resubmit-the-dsuvia-new-drug-application-in-q2-idUSASB0C9J8", "ord_in_thread": 0, "title": "BRIEF-AcelRX Plans To Resubmit The Dsuvia New Drug Application In Q2", "locations": [], "entities": {"persons": [{"name": "acelrx", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "acelrx pharmaceuticals inc", "sentiment": "negative"}, {"name": "thomson reuters trust principles", "sentiment": "none"}, {"name": "utes", "sentiment": "none"}, {"name": "nda", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "crl", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 8 (Reuters) - Acelrx Pharmaceuticals Inc:\n* ACELRX ANNOUNCES RECEIPT OF TYPE A FDA MEETING MINUTES AND PLANS TO RESUBMIT THE DSUVIA NEW DRUG APPLICATION IN Q2 2018\n* ACELRX PHARMACEUTICALS INC - ‍INTENDS TO RESUBMIT NDA IN Q2 OF 2018 AFTER COMPLETION OF HF STUDY​\n* ACELRX PHARMACEUTICALS - ‍RECEIPT OF OFFICIAL JANUARY 2018 TYPE A MEETING MINUTES FROM U.S. FDA RELATING TO ACELRX’S DSUVIA NDS\n* ACELRX PHARMACEUTICALS INC - ‍ACELRX PROPOSED POTENTIAL RESOLUTIONS FOR TWO MAIN POINTS IDENTIFIED IN CRL RECEIVED FROM FDA IN OCTOBER 2017​\n* ACELRX PHARMACEUTICALS INC - CO PROPOSED INSTEAD TO REDUCE MAXIMUM DOSE IN LABEL TO NOT EXCEED 12 TABLETS WITHIN A 24-HOUR PERIOD\n* ACELRX PHARMACEUTICALS INC - CO SUBMITTED TO FDA UPDATED DFU, AND A REVISED PROTOCOL FOR HF STUDY REQUIRED TO VALIDATE EFFECTIVENESS OF DFU CHANGES​ Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles.", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-09T05:22:00.000+02:00", "crawled": "2018-03-09T14:09:38.006+02:00", "highlightTitle": ""}